Our Take
Boston's cluster crown is slipping not from lack of science but from overconstruction and a pivot by mid-cap firms toward owning supply chain assets, a structural shift that favors regions with cheap land and manufacturing density.
Why it matters
Real estate vacancies and layoffs signal a rebalancing of biopharma geography after decades of Boston dominance. If you're betting on cluster location for hiring, capital, or real estate strategy, the map is redrawn.
Do this week
Portfolio leads: audit your lease renewals in Boston and Cambridge against the Bay Area and BioHealth Capital Region vacancy rates (33.7% and lower) before committing multi-year space this quarter.
Boston's Lab Glut Deepens as Mid-Caps Shift to Ownership
Boston and Cambridge, long the nation's largest biopharma cluster by lab inventory (63.2 million square feet per MassBio), now face a 32.7% availability rate—up 70 basis points from Q1 2025 (per CBRE). The region added $6.85 billion in venture capital in 2025 and $1.59 billion in Q1 2026, yet shedding jobs: Takeda eliminated 247 in Massachusetts in March as part of a $1.3 billion global restructuring. Replimune cut 223 jobs at its Woburn headquarters and Framingham manufacturing site after an FDA rejection. In February, Takeda placed 449,140 square feet on the sublease market.
The underlying cause is a structural shift in how mid-cap biopharmas (those with $2 billion to $10 billion market cap) acquire real estate. They are buying lab and manufacturing properties to control supply chains, rather than leasing, according to Matthew Gardner, CBRE Americas Life Sciences Leader. This trend is "coast-to-coast in most of the major centers." Meanwhile, real estate investment trusts are pivoting: Alexandria Real Estate Equities scrapped plans to convert 401 Park Drive in Boston into lab space in February, with the CEO citing a pivot toward office demand. A REIT investor shift from pure-play biopharma real estate to broader healthcare portfolios is underway, exemplified by Healthpeak's $600 million acquisition of a 1.4-million square foot campus in South San Francisco from Alexandria and Boston Properties in December 2025–January 2026.
Boston still attracts large tenants. Genentech agreed to triple its space from 30,000 to 100,000 square feet at One Milestone Street in the Harvard University-owned Enterprise Research Campus in Allston. Three companies priced IPOs in late April: Hemab Therapeutics and Seaport Therapeutics raised $301.5 million and $254.88 million respectively; Avalyn Pharma raised $300 million. Eli Lilly acquired Boston-based Kelonia Therapeutics (up to $7 billion) and Cambridge-based Ajax Therapeutics (up to $2.3 billion) in April. But these wins are offset by a wider contraction in available space and employment.
Manufacturing and Capital Climate Are Remaking the Map
Two macro forces explain the shift. First, global biopharma giants are "reshoring" manufacturing to the U.S. to meet surging demand for obesity drugs and to avoid tariffs. This is flooding regions like North Carolina, Greater Philadelphia, Maryland, Virginia, and emerging clusters with new facilities. AstraZeneca announced $2 billion in Maryland manufacturing expansion in November and a $4.5 billion project in Rivanna Futures, Virginia, creating 600 permanent jobs. Eli Lilly is building a $5 billion API facility in Goochland County, Virginia. Merck broke ground on a $3 billion Center of Excellence in Elkton, Virginia.
Second, the venture and M&A climate has improved, and mid-caps are using capital to buy rather than lease. This breaks a pattern: leasing was the default for cash-constrained companies. Ownership offers operational control and hedge against future rent spikes, especially as Boston and the Bay Area face overlarge inventory. The Bay Area itself shows signs of strain (33.7% availability per CBRE), but has momentum in AI partnerships—Nvidia and Eli Lilly announced a $1 billion, five-year co-innovation lab there in January—and less recent speculative overbuilding than Boston.
Where to Watch and What Numbers Matter
The 2026 top-10 cluster rankings rest on five metrics: patents (from USPTO database), NIH funding (through May 2026 and all of FY 2025), venture capital (2025 and Q1 2026 via PitchBook and regional groups), lab space (total square feet), and jobs. Boston ranks first in lab space but only fifth in jobs (117,108 per MassBio). The Bay Area leads in venture capital ($7.8 billion in 2025, $1.5 billion in Q1 2026) and second in jobs ("more than 147,000" per CBRE). BioHealth Capital Region benefits from reshoring tailwinds and lower existing vacancy.
If you are planning expansions, hiring, or leasing commitments, geography now carries real cost and talent implications. Boston's size masks a local employment contraction. The Bay Area's strength in VC and partnerships coexists with high vacancy. The BioHealth Capital Region is absorbing the largest capital commitments from global manufacturers. The data shows the map is not static; it rewards regions aligned with current capital flows (ownership, manufacturing, AI partnerships) and punishes those relying on legacy cluster density.